The synergistic antitumor study demonstrated that exosomes isolated from MSCCXCR4+TRAIL (exosomeCXCR4+TRAIL) were essential as a cooperative agent with carboplatin (an anticancer drug) in an MDA-MB-231Br SCID mouse model, potentially creates a new strategy to advance the treatment of breast cancer brain metastases. Here, TNFSF10 is linked to breast carcinoma.